KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $7.4 million.

  • Esperion Therapeutics' Other Non-Current Liabilities changed N/A to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year change of. This contributed to the annual value of $240.0 million for FY2023, which is 964.38% up from last year.
  • Per Esperion Therapeutics' latest filing, its Other Non-Current Liabilities stood at $7.4 million for Q3 2025.
  • Over the past 5 years, Esperion Therapeutics' Other Non-Current Liabilities peaked at $265.0 million during Q3 2022, and registered a low of $7.4 million during Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' median Other Non-Current Liabilities value was $233.5 million (recorded in 2021), while the average stood at $203.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 4572.5% in 2021, then crashed by 1307.73% in 2023.
  • Esperion Therapeutics' Other Non-Current Liabilities (Quarter) stood at $245.7 million in 2021, then fell by 10.95% to $218.8 million in 2022, then grew by 9.64% to $240.0 million in 2023, then fell by 1.48% to $236.4 million in 2024, then crashed by 96.85% to $7.4 million in 2025.
  • Its Other Non-Current Liabilities was $7.4 million in Q3 2025, compared to $7.4 million in Q2 2025 and $236.4 million in Q1 2024.